Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MorphoSys has started dosing in a multi-centre, open-label, dose- escalation Phase 1/2a trial evaluating its cancer antibody MOR202.
Subscribe to our email newsletter
The trial aims to investigate the safety and preliminary efficacy of MOR202 in patients with relapsed or refractory multiple myeloma.
In the trial, the patients with relapsed or refractory multiple myeloma are expected to be treated with different doses of the HuCAL-derived antibody MOR202.
MorphoSys chief development officer Arndt Schottelius said they will evaluate MOR202 both as a monotherapy and in combination with standard therapy.
"In total, this is our third proprietary antibody program in clinical trials, following MOR103 in rheumatoid arthritis and MOR208 in chronic lymphocytic leukemia," Schottelius said.